MicroPort EP

MicroPort EP (branded internationally as MicroPort EverPace) operates as a subsidiary of MicroPort Scientific Corporation (HKEX: 00853), specializing in cardiac electrophysiology devices for arrhythmia diagnosis and treatment. The company listed on Shanghai’s STAR Market in August 2022.

Company Overview

Established in the Shanghai International Medical Zone, MicroPort EP has developed into China’s first domestic manufacturer capable of providing complete 3D electrophysiology equipment and consumable solutions. The company’s product portfolio spans three major ablation energy modalities: radiofrequency, cryoablation, and pulsed field ablation.

As of late 2024, MicroPort EP products serve over 1,000 hospitals across 31 provinces in China and have expanded to more than 30 countries globally. The company achieved STAR Market listing on August 31, 2022, exactly twelve years after its founding date.

Core Products

Columbus 3D EP Navigation System

The flagship Columbus system represents China’s first domestically developed magnetic localization-based 3D electrophysiology navigation system. Receiving NMPA approval in October 2020, Columbus has supported over 50,000 procedures globally as of 2023. The system integrates electromagnetic dual-modality tracking with cardiac motion compensation, enabling real-time catheter visualization during ablation procedures.

Genesis RMN Robotic Magnetic Navigation System

Through a strategic partnership with Stereotaxis (NYSE: STXS) announced in August 2021, MicroPort EP serves as the exclusive distributor for the Genesis RMN system in China. The robotic platform received NMPA approval in November 2024, enabling minimally invasive catheter navigation using low-intensity magnetic fields for complex cardiac ablation procedures.

Ablation Catheter Portfolio

The company manufactures multiple catheter lines including:

• FireMagic TrueForce: Contact force-sensing irrigated RF ablation catheter with CE and UKCA certifications
• Magbot: Magnetic navigation catheter developed with Stereotaxis, NMPA approved December 2024
• IceMagic: China’s first domestically developed cryoablation system, approved August 2023

Technology & Innovation

MicroPort EP holds National Specialized and Sophisticated “Little Giant” Enterprise status (2022). Multiple products have entered NMPA’s Innovation Green Channel, including the Columbus system, IceMagic cryoablation platform, and EasyEcho ultrasound catheter (approved for fast-track registration in April 2025).

The company’s R&D focuses on three technology platforms:

1. Magnetic-based 3D navigation with sub-millimeter accuracy
2. Multi-energy ablation (RF, cryo, pulsed field)
3. Robotic catheter navigation through Stereotaxis partnership

Market Presence

MicroPort EP products cover all 31 provinces in mainland China with installations in over 1,000 hospitals. International expansion includes CE-marked products in European markets, with clinical applications completed in Spain, Poland, Greece, and Thailand.

The Stereotaxis collaboration positions MicroPort EP as China’s gateway for robotic magnetic navigation technology in cardiac electrophysiology.

Key Milestones

• 2010: Company founded in Shanghai International Medical Zone
• 2015: Columbus system enters NMPA Innovation Green Channel
• 2020: Columbus V3 receives NMPA approval; CNY 300M strategic funding round
• 2021: Stereotaxis partnership announced
• 2022: STAR Market IPO (688351.SH); National “Little Giant” designation
• 2023: IceMagic cryoablation system approved; Columbus procedures exceed 50,000
• 2024: Genesis RMN (November) and Magbot catheter (December) receive NMPA approval

Frequently Asked Questions

What products does MicroPort EP manufacture?

MicroPort EP develops cardiac electrophysiology devices including 3D navigation systems (Columbus), ablation catheters (FireMagic, IceMagic), diagnostic catheters (EasyFinder, EasyLoop), and distributes robotic navigation systems (Genesis RMN) in China.

Is MicroPort EP the same as MicroPort MedBot?

No. Both are subsidiaries of MicroPort Scientific Corporation but operate independently. MicroPort EP focuses on cardiac electrophysiology, while MicroPort MedBot develops surgical robots for laparoscopic and orthopedic procedures.

Does MicroPort EP have robotic products?

MicroPort EP distributes the Genesis RMN robotic magnetic navigation system in China through partnership with Stereotaxis. The company also co-developed the Magbot catheter specifically designed for robotic navigation procedures.